Prescribing a Path for PDTs

With prescription digital therapeutics facing exponential growth in the next five years, ensuring approval pathways for these treatments is critical. Beth Beck, Head of Fingerpaint’s Saratoga Springs Office, and Roshawn Blunt, Managing Director of 1798, are among experts tapped to share insights on regulatory considerations and demonstrating value to payers in the evolving PDT market in this MedAdNews special feature.

Beck stresses the importance of helping manufacturers address how PDT prescribing impacts the workflow efficiency for physicians.

Blunt explains the role evidence will play for payers in determining coverage for PDTs:

“Although every payer will still have differences in what they require as evidence, the pilots may be one of the best pathways that organizations have to getting that utilization put in place.”

Connect with Beck and Blunt on LinkedIn.